During the past decade, Texas Oncology Cancer Care and Research Center conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 15 clinical trials were completed, i.e. on average, 375% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 5 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Texas Oncology Cancer Care and Research Center" #1 sponsor was "Novartis Pharmaceuticals" with 5 trials, followed by "Bristol-Myers Squibb" with 4 trials sponsored, "US Oncology Research" with 4 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored and "Agennix" with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Oncology Cancer Care and Research Center" #1 collaborator was "Pfizer" with 3 trials as a collaborator, "US Oncology Research" with 3 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator and "Memorial Sloan Kettering Cancer Center" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Texas Oncology Cancer Care and Research Center" are "Breast Cancer" (4 trials), "Metastatic Breast Cancer" (3 trials), "Non-Small Cell Lung Cancer" (3 trials), "Prostate Cancer" (3 trials) and "Small Cell Lung Cancer" (2 trials). Many other conditions were trialed in "Texas Oncology Cancer Care and Research Center" in a lesser frequency.

Most popular intervention types in "Texas Oncology Cancer Care and Research Center" are "Drug" (26 trials) and "Other" (3 trials). Other intervention types were less common.

The name of intervention was led by "Prednisone" (3 trials), "docetaxel" (3 trials), "Abemaciclib" (2 trials), "Amrubicin" (2 trials) and "Bevacizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Texas Oncology Cancer Care and Research Center" are 16 trials for "All" genders, 6 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Texas Oncology Cancer Care and Research Center". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 21 completed trials in Texas Oncology Cancer Care and Research Center, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Texas Oncology Cancer Care and Research Center, 1 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".